TrialCancer research communications2024

Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma.

Edgar Gonzalez-Kozlova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.